Figure 2 from p97 Inhibition Synergistically Enhances Hypomethylating Therapy through Targeting of PLK1 in Acute Myeloid Leukemia
Year: 2026
Type: other
Abstract: The combination of CB-5339 and DAC has synergistic antileukemic activity. A, CB-5339 and DAC cooperate to diminish AML cell viability in seven AML cell lines. AML cell lines were treated with 300 nmol/L DAC, 200 nmol/L CB-5339, or combinations for 72 hours. Cell viability was determined by MTT assay. N = 3 ± SD; * indicates significant difference from control and single agent groups, P < 0.005. B, Heatmaps of formal synergy analysis of the combination of CB-5339 and DAC in four representative AML cell lines. C, CB-5339 and DAC have synergistic and selective antileukemic activity against primary AML cells from patients with adverse features. Primary AML cells from patients (N = 5) and normal CD34+ bone marrow cells were treated with 500 nmol/L DAC, 250 nmol/L CB-5339, or the combination for 72 hours. Cell viability was determined by MTT assay. N = 3 ± SD; * indicates a significant difference from control and monotherapies, P < 0.005. D, AML patient characteristics. E, The CB-5339/DAC combination triggers synergistic levels of apoptosis. AML cells were treated with 250 nmol/L CB-5339, 500 nmol/L DAC, or the combination for 48 hours. Drug-induced apoptosis was quantified by PI/FACS analysis. N = 3 ± SD; * denotes a significant difference from control and single agents, P < 0.005.
Authors: Steffan T. Nawrocki, Ning Wang, Claudia M. Espitia, Harley Wu, Claudia Villa Celi, Julian Olea, Paniz Zarand, Homa Dadrastoussi, Hittu Matta, Sruthi Sureshkumar, Madison E. Gamble, Natalie L. Hakim, David Drum, Jack Angeles, Kaijin Wu, Jiang F. Zhong, Xuelian Chen, Alex Duong, Jennifer S. Carew, Kevin R. Kelly
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7166064554
Cites:
Cited by:
Related to: